Granules India Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "Press Release".
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Granules India reported strong Q4FY26 results with revenue from operations at INR 14,706 Mn, up 23% YoY, driven by growth in Europe (17% vs 8% last year) and a more diversified geographic mix. EBITDA grew 40% YoY to INR 3,521 Mn, with margins expanding to 24% from 21% in Q4FY25, reflecting improving earnings quality. PAT rose 33% YoY to INR 2,016 Mn. For the full year FY26, revenue grew 20% to INR 53,656 Mn and PAT grew 19% to INR 5,950 Mn. ROCE improved to 17.6% from 16.6%, and net debt fell sharply by INR 3,040 Mn YoY to INR 4,021 Mn, with net debt-to-EBITDA at a healthy 0.34x. The Chairman highlighted disciplined execution and progress in Complex Generics and the Peptides CDMO platform.
Strong broad-based growth with margin expansion and significant deleveraging signals improving business quality and should be viewed positively by shareholders. The combination of 40% EBITDA growth, 24% margins, and a 0.34x leverage ratio suggests the company is in a strong financial position heading into FY27.